|
Addgene inc
sars cov 2 spike protein Sars Cov 2 Spike Protein, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sars cov 2 spike protein/product/Addgene inc Average 94 stars, based on 1 article reviews
sars cov 2 spike protein - by Bioz Stars,
2026-05
94/100 stars
|
Buy from Supplier |
|
Addgene inc
frank stegmeier Frank Stegmeier, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/frank stegmeier/product/Addgene inc Average 93 stars, based on 1 article reviews
frank stegmeier - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
toronto knockout tko crispr library ![]() Toronto Knockout Tko Crispr Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/toronto knockout tko crispr library/product/Addgene inc Average 93 stars, based on 1 article reviews
toronto knockout tko crispr library - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
addgene pooled library ![]() Addgene Pooled Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/addgene pooled library/product/Addgene inc Average 93 stars, based on 1 article reviews
addgene pooled library - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
fernando camargo ![]() Fernando Camargo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/fernando camargo/product/Addgene inc Average 93 stars, based on 1 article reviews
fernando camargo - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
feng zhang ![]() Feng Zhang, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/feng zhang/product/Addgene inc Average 93 stars, based on 1 article reviews
feng zhang - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
toronto knockout crispr library version 3 ![]() Toronto Knockout Crispr Library Version 3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/toronto knockout crispr library version 3/product/Addgene inc Average 94 stars, based on 1 article reviews
toronto knockout crispr library version 3 - by Bioz Stars,
2026-05
94/100 stars
|
Buy from Supplier |
|
Addgene inc
sgrna library ![]() Sgrna Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sgrna library/product/Addgene inc Average 93 stars, based on 1 article reviews
sgrna library - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
john doench ![]() John Doench, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/john doench/product/Addgene inc Average 96 stars, based on 1 article reviews
john doench - by Bioz Stars,
2026-05
96/100 stars
|
Buy from Supplier |
|
Addgene inc
sabatini lander human crispr pooled library ![]() Sabatini Lander Human Crispr Pooled Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sabatini lander human crispr pooled library/product/Addgene inc Average 93 stars, based on 1 article reviews
sabatini lander human crispr pooled library - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
Addgene inc
human crispri dual sgrna libraries ![]() Human Crispri Dual Sgrna Libraries, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human crispri dual sgrna libraries/product/Addgene inc Average 95 stars, based on 1 article reviews
human crispri dual sgrna libraries - by Bioz Stars,
2026-05
95/100 stars
|
Buy from Supplier |
|
Addgene inc
lentiviral sgrna library ![]() Lentiviral Sgrna Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/lentiviral sgrna library/product/Addgene inc Average 94 stars, based on 1 article reviews
lentiviral sgrna library - by Bioz Stars,
2026-05
94/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Discover Oncology
Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook
doi: 10.1007/s12672-025-03383-5
Figure Lengend Snippet: Generation of pancreatic cancer models employing a range of CRISPR systems. Various CRISPR gene editing techniques are instrumental in generating GEMMs. Among them, CRISPR/Cas9 plays a pivotal role in the creation of transplantation models, either by modifying the genome of pancreatic cancer cells or by manipulating the immune system to facilitate PDX models. This system has also been widely applied in generating transgenic pancreatic cancer cell lines and genetically modified organoids, advancing research in cancer biology and therapeutic development
Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout ,
Techniques: CRISPR, Transplantation Assay, Transgenic Assay, Genetically Modified
Journal: Discover Oncology
Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook
doi: 10.1007/s12672-025-03383-5
Figure Lengend Snippet: Pooled CRISPR screening approaches in different experimental conditions. In direct in vivo screening, CRISPR is delivered into living organisms (e.g., mice) to induce genetic modifications in their natural biological context. In indirect in vivo screening, CRISPR is applied to cell lines or organoids derived from the in vivo model, which are then reintroduced into the organism, allowing for controlled exploration of genetic modifications. In vitro CRISPR screening is conducted in cultured cells for high-throughput gene editing and analysis of specific genetic targets. Sequencing technologies, such as NGS, are then used to identify novel oncogenes and druggable targets, providing insights into gene functions and the impact of specific genetic changes in isolated cells
Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout ,
Techniques: CRISPR, In Vivo, Derivative Assay, In Vitro, Cell Culture, High Throughput Screening Assay, Sequencing, Isolation
Journal: Discover Oncology
Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook
doi: 10.1007/s12672-025-03383-5
Figure Lengend Snippet: Therapeutic applications of CRISPR-driven gene editing. Through the targeted modification of key factors involved in the pathogenesis of pancreatic cancer, CRISPR systems, employing diverse mechanisms, offer promising prospects for advancing therapeutic strategies in the treatment of pancreatic cancer. PC pancreatic cancer
Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout ,
Techniques: CRISPR, Modification
Journal: Molecular cell
Article Title: CRAMP1 drives linker histone expression to enable Polycomb repression.
doi: 10.1016/j.molcel.2025.05.031
Figure Lengend Snippet: Figure 1. A genome-wide CRISPR-Cas9 genetic screen identifies an essential requirement for CRAMP1 and histone H1.4 in PRC2-mediated reporter repression (A) Schematic representation of GFP reporter repression by the PRC2 complex. (B) The GFP reporter is derepressed upon CRISPR-Cas9-mediated gene disruption of any of the three core PRC2 subunits, as assayed by flow cytometry. (C) A genome-wide CRISPR-Cas9 screen to identify factors required for PRC2 function. Following Cas9 expression in KBM-7 cells harboring the PRC2-sensitive GFP reporter, genome-wide mutagenesis was carried out with the Sabatini/Lander single guide RNA (sgRNA) library, 36 and GFP + cells isolated through two sequential rounds of FACS. ‘‘Significance’’ on the y axis represents the negative log of the ‘‘pos|score’’ metric reported by Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK). 37
Article Snippet: Single guide RNA (sgRNA) sequences were selected from the
Techniques: Genome Wide, CRISPR, Disruption, Flow Cytometry, Expressing, Mutagenesis, Isolation, Knock-Out
Journal: Molecular cell
Article Title: CRAMP1 drives linker histone expression to enable Polycomb repression.
doi: 10.1016/j.molcel.2025.05.031
Figure Lengend Snippet: Figure 5. Linker histones are not enriched at regions marked by H3K9me3 (A–D) Lack of linker histone enrichment at H3K9me3-marked genomic regions. (A) Tornado plots depicting linker histone CUT&Tag signal across H3K9me3 peaks from the ENCODE project; average signal intensity is shown in (B). (C) Heatmap depicting the lack of correlation between linker histone occupancy and H3K9me3. Cells are annotated with pairwise Spearman correlation coefficients. An example locus is shown in (D). (E) CUT&Tag faithfully profiles H3K9me3. Example loci comparing CUT&Tag versus H3K9me3 ChIP-seq data (ENCODE) are shown. (F and G) Linker histone insufficiency does not impair H3K9me3-dependent LINE-1 silencing by the HUSH complex. (F) Schematic representation of the dual- color reporter cell line designed to monitor both H3K9me3-dependent repression by the HUSH complex and linker histone-mediated PRC2-reporter repression. (G) HUSH-mediated LINE-1 silencing is unaffected upon CRAMP1 depletion. The indicated CRISPR sgRNAs were expressed in the dual-color reporter cell line, and GFP and iRFP fluorescence assayed by flow cytometry. See also Figure S5 and Table S2.
Article Snippet: Single guide RNA (sgRNA) sequences were selected from the
Techniques: ChIP-sequencing, CRISPR, Fluorescence, Flow Cytometry
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: ( A ) Comparison of growth phenotypes for all elements between our pilot single-sgRNA library and Horlbeck et al. data, merged by gene name (n=20,228 elements). Growth phenotypes are reported as γ (log 2 fold-enrichment of T final over T 0 , per doubling) and correlated between experiments (r=0.82). ( B ) Comparison of growth phenotypes for all elements between our pilot dual-sgRNA library and Horlbeck et al. data, merged by gene name (n=20,228 elements). Growth phenotypes are reported as γ and correlated between experiments (r=0.83). ( C ) Comparison of growth phenotypes for all elements between our pilot single- and dual-sgRNA libraries, merged by gene name (n=21,239 with 20,228 targeting elements and 1011 non-targeting elements). Growth phenotypes are reported as γ and correlated between experiments (r=0.86). ( D ) Comparison of true and false-positive rates in single element screens. ‘Positives’ (n=1363 elements) were defined as genes with a K562 CRISPRi growth screen p-value <0.001 and γ<–0.05 , and ‘negatives’ were defined as non-targeting control sgRNA pairs (n=1011 elements). ( E ) Comparison of recombination rates for non-targeting dual-sgRNA elements between replicates of our K562 growth screen. Non-targeting elements with a growth phenotype (γ>0.05 or γ<−0.05) were excluded (n=973 elements). Recombination rates were weakly correlated between replicates (r=0.30). ( f ) Comparison of recombination rates for all dual-sgRNA elements between replicates of our K562 growth screen (n=20,387 elements). Recombination rates were strongly correlated between replicates (r=0.77). ( G ) Comparison of recombination rates and growth phenotypes for all dual-sgRNA elements in our K562 growth screen (n=20,387 elements). Growth phenotypes are reported as γ. Recombination rates were strongly anticorrelated with growth phenotypes (r=−0.84).
Article Snippet: The
Techniques: Comparison, Control
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: ( A ) Schematics of CRISPRi transcription repressor domains and general lentiviral expression construct used for all CRISPRi effectors. UCOE = ubiquitous chromatin opening element; SFFV = spleen focus-forming virus promoter; P2A = ribosomal skipping sequence; WPRE = woodchuck hepatitis virus post-transcriptional regulatory element. Further information on repressor domains and lentiviral expression constructs can be found in the main text and Materials and methods. ( B ) Experimental design to test effects of stable expression of each CRISPRi effector on growth and transcription in K562 cells. ( C ) Growth defects of effector-expressing cells, measured as the log 2 of the ratio of mCherry-negative (effector-expressing) to mCherry-positive (not effector-expressing) cells in each well normalized to the same ratio on day 0. mCherry levels were measured for 19 days after pooling cells. Data represent mean ± SD from three independent transductions of expression constructs. p-Values are from an unpaired two-tailed t-test comparing D19 values for each sample to the D19 value for the ‘no plasmid’ sample. Average percent growth defect per day is the log 2 D19 value divided by the number of days, multiplied by 100 for a percent value. ( D ) Clustered heatmap of correlation of transcript counts from K562 cells expressing indicated CRISPRi effectors or a GFP control. Correlations across samples were calculated using normalized counts (reads per million) for all genes with mean normalized count >1 and then clustered using the Ward variance minimization algorithm implemented in scipy. r 2 is squared Pearson correlation. Data represent three independent transductions of expression constructs. ( E ) Number of differentially expressed genes ( p <0.05) for cells expressing each effector versus cells expressing GFP only. p -Values were calculated using a Wald test and corrected for multiple hypothesis testing as implemented in DeSeq2. Figure 2—source data 1. p-Values and growth defects depicted in . Figure 2—source data 2. Data depicted in .
Article Snippet: The
Techniques: Expressing, Construct, Virus, Sequencing, Two Tailed Test, Plasmid Preparation, Control
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: Design of constructs for CRISPR interference (CRISPRi) effector expression.
Article Snippet: The
Techniques: Construct, CRISPR, Expressing
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: ( A ) Experimental design to measure knockdown mediated by different CRISPR interference (CRISPRi) effectors by delivering single guide RNAs (sgRNAs) targeting either essential genes or cell surface markers. ( B ) Depletion of K562 cells expressing essential gene-targeting sgRNAs and different CRISPRi effectors, measured as the ratio of mCherry-positive (sgRNA-expressing) to mCherry-negative (not sgRNA-expressing) cells in a given well. mCherry levels were measured for 12 days after transduction, starting on day 3. Data from two replicate transductions. ( C ) Percent knockdown of cell surface markers by different CRISPRi effectors in K562 cells. Cell surface marker levels were measured on day 6 post-transduction by staining with an APC-conjugated antibody. Knockdown was calculated as the ratio of median APC signal in sgRNA-expressing cells and median APC signal in cells expressing a non-targeting control sgRNA after subtraction of background APC signal. Data from two replicate transductions. Cells expressing dCas9 and a strong CD55-targeting sgRNA are represented by a single replicate. ( D ) Distribution of anti-CD151 signal intensity (APC) in individual cells from one representative transduction. Data from second replicate are shown in . Knockdown was quantified as in C as the ratio of the median APC signals. ( E ) Percentage of cells without observable knockdown despite expressing a strong sgRNA, as quantified from the fluorescence distributions.
Article Snippet: The
Techniques: Knockdown, CRISPR, Expressing, Transduction, Marker, Staining, Control, Fluorescence
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: ( A ) Depletion of K562 cells expressing essential gene-targeting single guide RNAs (sgRNAs) and different CRISPRi effectors, measured as the ratio of mCherry-positive (sgRNA-expressing) to mCherry-negative (not sgRNA-expressing) cells in a given well, as in . mCherry levels were measured for 12 days after transduction, starting on day 3. Data from two replicate transductions. ( B ) Distribution of anti-CD151 signal intensity (APC) in K562 cells expressing indicated CRISPRi effectors from second replicate transduction. Knockdown was quantified as in . ( C ) Distribution of anti-CD81 signal intensity (APC) in K562 cells expressing indicated CRISPRi effectors from two replicate transductions. Knockdown was quantified as in . ( D ) Distribution of anti-CD55 signal intensity (APC) in K562 cells expressing indicated CRISPRi effectors from two replicate transductions. Cells expressing dCas9 and the CD55-targeting sgRNA are represented by a single replicate. Knockdown was quantified as in .
Article Snippet: The
Techniques: Expressing, Transduction, Knockdown
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet: ( A ) Distribution of anti-B2M signal intensity (APC) in individual RPE1 (left) and Jurkat (right) cells expressing indicated CRISPR interference (CRISPRi) effectors and single guide RNAs (sgRNAs). Knockdown was calculated as the ratio of median APC signal in transduced (sgRNA-expressing) cells and median APC signal in non-transduced cells in the same well, after subtraction of background APC signal. ( B ) Depletion of indicated cell surface markers in HepG2 (top), HuTu-80 (middle), and HT29 (bottom) cells expressing Zim3-dCas9. Cell surface marker levels were measured 6–14 days post-transduction by staining with APC-conjugated antibodies. Knockdown was calculated as the ratio of median APC signal in sgRNA-expressing cells and median APC signal in cells expressing a non-targeting control sgRNA after subtraction of background APC signal. ( C ) Distribution of anti-B2M signal intensity (APC) in individual K562 cells expressing indicated CRISPRi effectors and sgRNAs. The Zim3-dCas9 (Hygro) cell line was generated by transduction followed by hygromycin selection and does not express a fluorescent protein. Knockdown was calculated as in A .
Article Snippet: The
Techniques: Expressing, CRISPR, Knockdown, Marker, Transduction, Staining, Control, Generated, Selection
Journal: eLife
Article Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
doi: 10.7554/eLife.81856
Figure Lengend Snippet:
Article Snippet: The
Techniques: Stable Transfection, Marker, Flow Cytometry, Recombinant, Plasmid Preparation, Sequencing, Expressing, Purification, Amplification, Transfection, Software, Genome Wide